List of Excipients in Branded Drug VANOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	VANOS	fluocinonide	54868-6204	CARBOMER HOMOPOLYMER TYPE C
Physicians Total Care Inc	VANOS	fluocinonide	54868-6204	CITRIC ACID MONOHYDRATE
Physicians Total Care Inc	VANOS	fluocinonide	54868-6204	DIISOPROPANOLAMINE
Physicians Total Care Inc	VANOS	fluocinonide	54868-6204	DIMETHYL ISOSORBIDE
Physicians Total Care Inc	VANOS	fluocinonide	54868-6204	GLYCERYL MONOSTEARATE

Vanos Excipient Strategy and Commercial Opportunities for Fluocinonide 0.1% Cream

Last updated: August 9, 2026

Vanos is a prescription topical corticosteroid containing fluocinonide 0.1%. Its commercial value is tied less to new-molecule exclusivity than to vehicle performance, generic substitution, tolerability, adherence, and differentiated delivery formats. The strongest opportunities are preservative-reduced formulations, improved sensory properties, low-transfer vehicles, and products designed for specific body sites or patient groups.

What is Vanos and which excipients does it contain?

Vanos Cream is a high-potency topical corticosteroid indicated for corticosteroid-responsive dermatoses in patients aged 12 years and older. It is also indicated for plaque psoriasis involving non-scalp areas, subject to labeled duration and quantity limits.[1]

The FDA labeling identifies the following inactive ingredients:

Excipient	Likely formulation function
Propylene glycol	Humectant, solvent, penetration enhancer
Glyceryl stearate	Emulsifier and emollient
Stearyl alcohol	Consistency agent and emollient
White petrolatum	Occlusive emollient
Methylparaben	Preservative
Citric acid	pH adjustment
Sodium citrate	Buffering agent
Edetate disodium	Chelating agent
Purified water	Aqueous phase

The formulation is an oil-in-water cream designed to balance corticosteroid delivery with spreadability and moisturization. Propylene glycol can improve solubilization and skin penetration but may cause irritation or allergic contact dermatitis in susceptible patients. White petrolatum increases occlusivity and moisturization but can make the product feel greasy and increase transfer to clothing.

Vanos is therefore a useful benchmark for a conventional dermatology cream, but its excipient profile leaves room for differentiated products targeting cosmetic acceptability, sensitive skin, and adherence.

What excipient functions matter most in a fluocinonide cream?

Drug solubilization and uniformity

Fluocinonide is a potent, poorly water-soluble corticosteroid. The vehicle must maintain uniform drug distribution during manufacturing, filling, storage, and use. Propylene glycol and the oil phase contribute to drug solubilization and distribution.

A generic or follow-on manufacturer must control:

• Particle size and polymorphic form of fluocinonide
• Drug concentration throughout the emulsion
• Phase separation
• Crystallization during storage
• Assay and content uniformity
• Viscosity and rheology
• In-use stability after repeated tube opening

The commercial risk is not limited to chemical assay. A formulation can meet potency specifications while producing different release or permeation behavior because of changes in particle size, emulsifier concentration, solvent ratio, or microstructure.

Skin penetration

For a potent topical corticosteroid, increased penetration can improve efficacy but also raise the risk of local and systemic corticosteroid adverse effects. The excipient strategy must therefore optimize delivery rather than maximize penetration.

Potential penetration-enhancing components include:

• Propylene glycol
• Certain glycols and glycol ethers
• Fatty alcohols
• Selected surfactants
• Lipid-based delivery systems
• Microemulsion or nanoemulsion structures

A formulation with substantially greater penetration may require additional clinical or comparative performance evidence. The commercial objective should be controlled and reproducible delivery, especially for thick plaques, rather than the highest possible flux.

Rheology and application behavior

Patients use topical steroids inconsistently when creams are difficult to spread, sticky, slow to absorb, or visibly glossy. Rheology is commercially important because it affects:

• Dose uniformity during application
• Spread area per gram
• Residence time on skin
• Clothing transfer
• Perceived absorption
• Reapplication behavior
• Patient adherence

Vanos uses a cream format that supplies moisturization and occlusion. A competing product could differentiate through a lighter cream, fast-absorbing emulsion, gel-cream, lotion, spray, or foam. Each format creates different manufacturing, stability, packaging, and regulatory requirements.

How strong is the Vanos formulation patent estate?

Vanos is an older topical product, and its principal market protection is unlikely to be driven by active-ingredient exclusivity. Fluocinonide has been used in prescription dermatology for decades. The practical competitive barriers are more likely to involve formulation patents, manufacturing know-how, trademarks, FDA regulatory exclusivity history, and physician or patient familiarity.

Active ingredient and regulatory exclusivity

Vanos was approved under FDA NDA 021242. The product’s new-drug exclusivity period has expired. A five-year new chemical entity exclusivity period would not be expected to remain relevant for a product approved in 2003.[1][2]

The relevant current questions are:

1. Whether Vanos-specific formulation patents remain enforceable.
2. Whether those patents were listed in the Orange Book.
3. Whether listed patents cover the marketed cream, an approved use, or a delivery technology.
4. Whether any listed patent has a later expiration date than the underlying drug exclusivity.
5. Whether an ANDA applicant must provide a Paragraph IV certification.

A complete live patent conclusion requires current review of the FDA Orange Book, USPTO records, terminal disclaimers, assignment history, and any litigation docket. The available product information supports a formulation-focused commercial analysis, but it does not establish a current, exhaustive Vanos patent list.

What is the Orange Book status of Vanos?

Vanos is an FDA-approved prescription product, but approval does not by itself establish continuing patent protection. Orange Book status depends on the current listed patents for the NDA and the status of any approved generic equivalents.

The key Orange Book data points are:

Issue	Commercial relevance
NDA 021242 listing	Identifies the reference product
Dosage form	Cream
Strength	Fluocinonide 0.1%
Route	Topical
Listed patents	May require Paragraph IV certification
Reference-listed drug status	Controls ANDA bioequivalence reference
Therapeutic equivalence codes	Indicate substitutability of approved generics

Topical products can present more complex generic-development issues than oral tablets. FDA may evaluate formulation sameness, physicochemical characteristics, drug release, and comparative performance. The regulatory pathway depends on the product and the applicable FDA guidance in force at filing.

When does Vanos lose exclusivity and when can generics launch?

Vanos lost its original FDA regulatory exclusivity years ago. Generic launch timing depends on patent certifications, litigation, settlement terms, approval status, and commercial strategy.

Generic launch scenarios

Scenario	Likely commercial effect
No blocking patent	ANDA approval can permit prompt launch
Paragraph III certification	Launch follows patent expiration
Paragraph IV certification with no litigation	Approval may proceed after regulatory requirements are met
Paragraph IV litigation filed within 45 days	FDA approval may face a 30-month stay, subject to statutory exceptions
Patent settlement	Launch date depends on negotiated terms
Authorized generic	Can reduce branded price and accelerate substitution

For Vanos, the commercial question is not whether generic fluocinonide exists in the abstract. It is whether a generic is therapeutically equivalent to the specific 0.1% cream presentation and whether pharmacies can substitute it under state law and payer policy.

What formulation patents could protect a Vanos follow-on product?

A new product would have the strongest patent position if its claims covered a technically specific formulation that produced a measurable performance advantage.

Potential patentable formulation categories

Low-irritancy vehicles

A formulation could target patients who experience irritation from propylene glycol, parabens, or surfactants. Possible approaches include:

• Propylene-glycol-reduced or propylene-glycol-free creams
• Alternative preservatives
• Preservative-free single-use packaging
• Lower-surfactant emulsions
• pH-optimized systems
• Reduced fragrance and allergen burden

A patent would need more than a routine excipient substitution. Stronger claims would link composition ranges to improved stability, reduced irritation, enhanced release, or a defined clinical use.

Improved cosmetic acceptability

Commercial differentiation could come from:

• Non-greasy creams
• Rapidly absorbed emulsions
• Low-residue vehicles
• Reduced white cast
• Reduced clothing transfer
• Improved washability
• Better spreadability over large body areas

These benefits can support formulation patents, trade secrets, product branding, and payer negotiations, although consumer-perceived advantages are difficult to defend without objective testing.

Site-specific delivery

Different body sites have different penetration and tolerability requirements. Potential products include:

• A low-transfer cream for trunk and limbs
• A lighter lotion for large surface areas
• A foam or solution for hair-bearing areas
• A scalp formulation
• A controlled-residence formulation for plaques
• A low-occlusion product for intertriginous areas

The clinical indication and labeling must match the safety profile of the vehicle and the potency of fluocinonide.

Controlled release

Polymeric gels, lipid particles, microemulsions, and structured emulsions could attempt to reduce burst release and extend residence time. These systems may support patent claims around:

• Particle size
• Polymer composition
• Drug loading
• Release profile
• Skin retention
• Reduced systemic exposure
• Manufacturing process parameters

The regulatory burden increases if the product is materially different from the reference cream.

Which excipient strategies offer the best commercial opportunity?

1. Preservative-reduced or preservative-free fluocinonide

A preservative-free version could target patients with compromised skin barriers or known preservative sensitivity. Single-dose sachets, unit-dose tubes, or airless pumps could reduce microbial exposure.

The main barriers are packaging cost, dose waste, manufacturing complexity, and stability after opening. For a low-cost generic, the economics may not support these features. For a branded dermatology product, they could support premium pricing.

2. Propylene-glycol-free formulation

Propylene glycol is useful but can create tolerability concerns. Replacing it with alternative solvents or humectants may create a clinically meaningful niche.

The replacement must preserve:

• Fluocinonide solubility
• Homogeneous dosing
• Release performance
• Physical stability
• Skin feel
• Microbial robustness

A successful product could be positioned for patients with irritation, allergic contact dermatitis, or poor adherence linked to burning or stinging.

3. Fast-absorbing, low-transfer cream

A low-transfer vehicle addresses a common practical problem with topical therapy. It could be positioned for daytime use, working adults, and treatment of visible or clothing-contact areas.

Commercial advantages may include:

• Better adherence
• Higher patient satisfaction
• Lower perceived messiness
• Reduced product loss on clothing
• Improved application convenience

This strategy is more commercially plausible than a high-penetration formulation because it improves use without necessarily increasing corticosteroid exposure.

4. Foam, lotion, or spray delivery

A foam or spray can improve treatment of scalp and hair-bearing areas. A lotion can improve coverage of large body areas. These products could compete with other topical corticosteroid formats rather than directly replacing Vanos Cream in every use.

The main development risks are propellant selection, container compatibility, dose metering, flammability labeling, preservative control, and scale-up.

5. Combination products

A fluocinonide combination with an antimicrobial, antifungal, keratolytic, or barrier-repair ingredient could create a differentiated product. Combination products face higher regulatory and clinical complexity and may raise safety concerns, particularly when high-potency corticosteroids are used with other active ingredients.

A nonprescription barrier-repair companion product may be commercially safer than a new combination drug. It could use ceramides, glycerin, petrolatum, colloidal oatmeal, or other moisturizers to support maintenance therapy after the corticosteroid course.

What manufacturing and intellectual-property barriers exist?

Manufacturing know-how may be more important than patent duration for a topical emulsion. Key protected or difficult-to-reproduce parameters include:

• Order of phase addition
• Heating and cooling profile
• Homogenization energy
• Mixing speed and duration
• pH adjustment sequence
• Drug incorporation method
• Deaeration
• Filling temperature
• Tube and pump compatibility
• In-process viscosity controls

These parameters can be maintained as trade secrets even when broad formulation patents expire. A competitor may reproduce the qualitative composition but still obtain a different microstructure and release profile.

Packaging is also part of the product strategy. Laminated tubes, aluminum tubes, airless pumps, and unit-dose sachets provide different protection against oxygen, water loss, microbial contamination, and drug adsorption.

How does Vanos compare with generic fluocinonide products?

Attribute	Vanos	Conventional generic fluocinonide cream	Differentiated follow-on
Active ingredient	Fluocinonide 0.1%	Fluocinonide, strength depends on product	Fluocinonide with new vehicle
Primary value	Established brand and reference product	Price and substitution	Tolerability, adherence, delivery
Vehicle	Conventional cream	Usually conventional cream or approved equivalent	Foam, lotion, low-transfer cream, or specialized emulsion
Patent strategy	Legacy product and formulation rights	ANDA rights and freedom to operate	New composition, use, packaging, or process claims
Main risk	Generic erosion	Price competition	Clinical and regulatory complexity
Commercial positioning	Branded topical steroid	Low-cost substitute	Premium dermatology product

What revenue exposure and competitive risks affect Vanos?

The largest revenue risk is generic erosion once therapeutically equivalent products receive approval and pharmacy substitution becomes available. Payers generally favor lower-cost topical corticosteroids, especially when products are viewed as clinically interchangeable.

Vanos retains commercial value through:

• Brand recognition
• Prescriber familiarity
• Existing distribution
• Patient continuity
• Product availability
• Potentially distinct vehicle characteristics
• Contracting with health plans and pharmacy benefit managers

The revenue opportunity for a new excipient platform is stronger where the product can demonstrate an adherence, tolerability, or site-specific advantage. A merely cosmetic reformulation may struggle to justify premium pricing in a crowded topical steroid market.

What patent litigation and settlement issues should be monitored?

A Vanos-focused diligence review should monitor:

• Orange Book patent listings for NDA 021242
• ANDA Paragraph IV notices
• District court litigation under the Hatch-Waxman framework
• Federal Circuit decisions involving topical dermatology products
• Patent settlements containing launch dates or licenses
• Authorized-generic arrangements
• FDA approval letters for generic fluocinonide 0.1% products
• Patent assignments involving Vanos-related formulations

The absence of a known public dispute does not establish that no patent rights, licenses, or confidential settlement terms exist. Commercial launch analysis must distinguish public litigation records from private contractual restrictions.

Key Takeaways

• Vanos is fluocinonide 0.1% cream, an established high-potency topical corticosteroid.
• Its excipient platform relies on conventional cream technology, including propylene glycol, fatty alcohols, petrolatum, buffering agents, and a preservative system.
• The strongest commercial opportunities are low-transfer creams, propylene-glycol-free vehicles, preservative-reduced products, and site-specific formats.
• Original FDA exclusivity is no longer a meaningful barrier to competition.
• Generic entry depends on current Orange Book listings, Paragraph IV certifications, litigation, approval status, and settlement terms.
• Formulation microstructure, process controls, packaging, and comparative performance are likely to be more important than the legacy brand alone.
• A premium follow-on product needs measurable tolerability, adherence, release, or application advantages to overcome generic price pressure.

Frequently Asked Questions

Is Vanos the same as fluocinonide cream?

Vanos is a branded product containing fluocinonide 0.1% in a cream vehicle. Other fluocinonide products may use different strengths, dosage forms, excipients, labeling, and approved indications.

Can propylene glycol be removed from a Vanos-type formulation?

Yes, but removal requires reformulation work to preserve fluocinonide solubility, uniformity, release, stability, microbial quality, and skin tolerability.

Is a Vanos follow-on product eligible for FDA approval as an ANDA?

Eligibility depends on whether the proposed product can meet the FDA requirements for a generic equivalent, including pharmaceutical equivalence, bioequivalence or applicable comparative performance requirements, labeling, and patent certification.

Could a new Vanos cream obtain method-of-use patent protection?

Potentially, but a method-of-use claim would need a new, non-obvious, and adequately supported therapeutic use. Routine treatment of the same labeled dermatoses would provide a weak basis for new patent protection.

Which packaging format best supports a preservative-free fluocinonide product?

Unit-dose sachets, single-use tubes, or well-designed airless pumps can reduce repeated microbial exposure. The optimal format depends on stability, dose requirements, manufacturing cost, and patient convenience.

References

1. U.S. Food and Drug Administration. (2003). Vanos (fluocinonide) cream, 0.1% prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic corticosteroids: In vivo bioequivalence.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. NDA 021242.